These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32061184)

  • 1. Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS-986260, mitigates class-based cardiovascular toxicity in dogs but not rats.
    Rak GD; White MR; Augustine-Rauch K; Newsome C; Graziano MJ; Schulze GE
    J Appl Toxicol; 2020 Jul; 40(7):931-946. PubMed ID: 32061184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical Profile of PF-06952229 (MDV6058), a Novel TGFβRI/Activin Like Kinase 5 Inhibitor Supports Clinical Evaluation in Cancer.
    Guha M; Thibault S; Pham S; Bernales S; Pai R; Herrera FJ; Johnson TR; Vitsky A; Fernando T; Finkelstein M
    J Pharmacol Exp Ther; 2024 Oct; 391(2):335-345. PubMed ID: 39284628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics-based approach for efficacious human dose projection of BMS-986260, a small molecule transforming growth factor beta receptor 1 inhibitor.
    Parrish KE; Swanson J; Cheng L; Luk E; Stetsko P; Smalley J; Shu YZ; Huang J; Pabalan JG; Sun Y; Zvyaga T; Cvijic ME; Burke J; Borzilleri R; Murtaza A; Augustine K; Yang Z
    Biopharm Drug Dispos; 2021 Apr; 42(4):137-149. PubMed ID: 33354831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition.
    Maher JM; Zhang R; Palanisamy G; Perkins K; Liu L; Brassil P; McNamara A; Lo A; Hughes AD; Kanodia J; Kulyk S; Nikula KJ; Dengler HS; Scandurra A; Lua I; Harstad E
    Toxicol Appl Pharmacol; 2022 Mar; 438():115905. PubMed ID: 35122773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent.
    Velaparthi U; Darne CP; Warrier J; Liu P; Rahaman H; Augustine-Rauch K; Parrish K; Yang Z; Swanson J; Brown J; Dhar G; Anandam A; Holenarsipur VK; Palanisamy K; Wautlet BS; Fereshteh MP; Lippy J; Tebben AJ; Sheriff S; Ruzanov M; Yan C; Gupta A; Gupta AK; Vetrichelvan M; Mathur A; Gelman M; Singh R; Kinsella T; Murtaza A; Fargnoli J; Vite G; Borzilleri RM
    ACS Med Chem Lett; 2020 Feb; 11(2):172-178. PubMed ID: 32071685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys.
    Mitra MS; Lancaster K; Adedeji AO; Palanisamy GS; Dave RA; Zhong F; Holdren MS; Turley SJ; Liang WC; Wu Y; Meng YG; Vernes JM; Schutten MM
    Toxicol Sci; 2020 May; 175(1):24-34. PubMed ID: 32077954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An innovative study design with intermittent dosing to generate a GLP-regulatory package in preclinical species for long lasting molecule M5717, inhibitor of Plasmodium eukaryotic translation elongation factor 2.
    Hewitt P; Abla N; Lignet F; Oeuvray C; Bagchus W; Bebrevska L
    Toxicol Appl Pharmacol; 2022 May; 443():116006. PubMed ID: 35367236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High hematocrit resulting from administration of erythropoiesis-stimulating agents is not fully predictive of mortality or toxicities in preclinical species.
    Andrews DA; Pyrah IT; Boren BM; Tannehill-Gregg SH; Lightfoot-Dunn RM
    Toxicol Pathol; 2014; 42(3):510-23. PubMed ID: 23674390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
    Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
    Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
    Bauss F; Russell RG
    Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer.
    Rizvi NA; Humphrey JS; Ness EA; Johnson MD; Gupta E; Williams K; Daly DJ; Sonnichsen D; Conway D; Marshall J; Hurwitz H
    Clin Cancer Res; 2004 Mar; 10(6):1963-70. PubMed ID: 15041713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
    Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
    Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.
    Peethambaram PP; Hartmann LC; Jonker DJ; de Jonge M; Plummer ER; Martin L; Konner J; Marshall J; Goss GD; Teslenko V; Clemens PL; Cohen LJ; Ahlers CM; Alland L
    Invest New Drugs; 2015 Apr; 33(2):321-31. PubMed ID: 25380635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy.
    Mausumee G; Frank S; Shawn C; Dara H; Zhao Y; Soleil PM; Sanderson TP; Michael G; Marc D
    Int J Toxicol; 2014 May; 33(3):204-218. PubMed ID: 24846376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
    Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
    Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
    Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC
    J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.
    Wang X; Kay A; Anak O; Angevin E; Escudier B; Zhou W; Feng Y; Dugan M; Schran H
    J Clin Pharmacol; 2013 Jan; 53(1):14-20. PubMed ID: 23400739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs.
    Mao Y; Xia Z; Zhang X; Zong Y; Zhu L; Yuan B; Lu G
    Food Chem Toxicol; 2012 May; 50(5):1256-70. PubMed ID: 22343322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.
    Yingling JM; McMillen WT; Yan L; Huang H; Sawyer JS; Graff J; Clawson DK; Britt KS; Anderson BD; Beight DW; Desaiah D; Lahn MM; Benhadji KA; Lallena MJ; Holmgaard RB; Xu X; Zhang F; Manro JR; Iversen PW; Iyer CV; Brekken RA; Kalos MD; Driscoll KE
    Oncotarget; 2018 Jan; 9(6):6659-6677. PubMed ID: 29467918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.